IndraLab
Statements
reach
"23 However, the KRAS variant is associated with a BRCA1 mutation like gene expression signature, supporting the notion that there might be increased oncogenic risk in the presence of the KRAS variant and high KRAS expression and low BRCA1 expression, either through mutation or other mechanisms."
reach
"Notably, overexpression of exogenous WT KRAS did not elicit additional tumor-suppressive effects in pancreatic cancer cells with endogenous WT KRAS expression (Fig. S4), signifying that it’s the presence of the WT allele, more than the dosage, that is more pertinent to its tumor-suppressive functions."
reach
"KRAS protein functions as a molecular switch cycling between ON and OFF state to affect the intracellular signaling.30 Whereas the ON switch to the active state is promoted by guanine nucleotide exchange factors (GEFs), the OFF state is regulated by GTPase-activating proteins (GAPs).33 Oncogenic alleles of KRAS lose the capability of GAP-induced GTP hydrolysis resulting in increased GTP-bound KRAS protein levels which in turn trigger the pro-growth signaling pathways."
reach
"These data indicated that upregulated H3 K27M might be a potent treatment target for diffuse midline glioma, H3 K27M-mutant exhibiting MASI of H3F3A K27M.There were previous studies where KRAS MASI elevated KRAS mRNA levels, increasing RAS activity [14, 24] and wild-type allele of KRAS has also been shown to play a pivotal role as a tumor suppressor [25]."
reach
"Oncogenic mutations in KRAS typically occur at hotspots in the protein (e.g., codons 12, 13, and 61), increasing the steady-state levels of KRAS proteins in the GTP-bound state that are capable of driving protumorigenic signaling through downstream effector pathways, such as the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways."